Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rosiridin is a bioactive monoterpene glycoside primarily derived from the roots of the plant *Rhodiola rosea* (Golden Root). It is recognized for its potential therapeutic effects in neuropsychiatric and neurodegenerative disorders. The primary mechanism of action involves the inhibition of monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B), enzymes responsible for the degradation of key neurotransmitters such as dopamine, serotonin, and norepinephrine. By preventing this degradation, rosiridin may enhance mood and provide neuroprotection. Research, including in vivo studies using rotenone-induced models, suggests that rosiridin possesses significant antioxidant and neuroprotective properties, making it a candidate for the management of Parkinson's disease and depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rosiridin.